CD80 and neoplasm: Notably, the expression levels of CD80 and CD40 on pDCs in tumor sites decreased in the shRNA-treated group (Figure 5A), whereas the activation of pDCs in spleen was not impaired (Figure S5A), suggesting that shRNA-induced tumor apoptosis might suppress the activation of pDCs.